Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
MWN-AI** Summary
Avacta Therapeutics announced significant advancements in its pre|CISION® platform, specifically with its FAP-cleavable payload delivery mechanism demonstrated through its investigational drug, FAP-Exd (AVA6103). In a recent analysis, Avacta highlighted the advantages of pre|CISION over the established antibody drug conjugate (ADC), Enhertu® (trastuzumab-deruxtecan). The analysis showcased three pivotal pharmacokinetic benefits: faster drug penetration into tumors, a higher absolute maximum concentration of the drug within the tumor, and a nearly three-fold increase in the Tumor Selectivity Index (TSI), which gauges the drug's effectiveness versus systemic exposure.
According to CEO Christina Coughlin, these findings underscore the potential of pre|CISION in enhancing therapeutic effects while limiting unwanted side effects associated with traditional ADCs. The data was generated through an innovative AI-driven approach, recreating a synthetic comparator arm that enabled a direct comparison of FAP-Exd with data sourced from Enhertu's clinical studies.
Moreover, the preliminary results suggest superior efficacy of FAP-Exd, especially in tumor models exhibiting low fibroblast activation protein (FAP) expression, and prolonged therapeutic responses over time compared to Enhertu. Avacta plans to initiate a Phase 1 clinical trial for FAP-Exd in Q1 2026, furthering its commitment to advancing cancer treatment with its proprietary delivery system.
The pre|CISION platform is uniquely designed to concentrate potent anticancer payloads specifically within tumor microenvironments, enhancing effectiveness while minimizing toxicity to normal tissues. As Avacta prepares for its upcoming clinical milestone, it remains optimistic about the potential success of FAP-Exd in the oncology landscape, highlighted by the promising results of its preclinical studies.
MWN-AI** Analysis
Avacta Therapeutics (AIM: AVCT) recently shared promising preclinical data regarding its pre|CISION platform, which showcases significant advantages compared to AstraZeneca's Enhertu®—a leading antibody-drug conjugate (ADC) currently approved for breast and gastric cancers. This innovative mechanism, designed to deliver therapeutics directly to tumors, is poised to enhance treatment efficacy while minimizing side effects, a growing concern in oncological therapies.
The experimental results from the FAP-Exd (AVA6103) program highlight key pharmacokinetic advantages that could position Avacta favorably in the competitive oncology landscape. Notably, the pre|CISION approach achieved a more rapid drug penetration into tumor tissues and demonstrated over a log higher maximum drug concentration (Cmax) within minutes, in stark contrast to Enhertu, which takes up to 24 hours to reach peak concentration. In addition, the Tumor Selectivity Index (TSI)—a critical measure of effectiveness and safety—was nearly three times greater for FV-Exd than T-Dxd, addressing the essential requirement for targeted tumor delivery.
These favorable attributes may not only enhance patient outcomes but also bolster Avacta's valuation as it progresses towards clinical trials. With the Phase 1 clinical study for AVA6103 set to commence in Q1 2026, market participants should keep an eye on Avacta’s developments, especially with the success of Enhertu underscoring the demand for effective oncological therapies.
Investors should consider positioning themselves in Avacta, given the compelling data supporting its pre|CISION delivery system and the anticipated clinical trial results. With a strong pipeline and increasing evidence of its innovations, Avacta appears poised for significant growth in the oncology sector. However, continued due diligence and monitoring of the company’s clinical outcomes and partnerships are recommended as the company moves forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu®
Clinical trial with AVA6103 is expected to be initiated in Q1 2026
LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform's compared to a marketed antibody drug conjugate (ADC).
The data analysis compares pre|CISION FAP-cleavable payload delivery with that of Enhertu®, a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product, trastuzumab-deruxtecan (T-Dxd), an exatecan-derivative ADC).
Avacta expects to initiate the Phase 1 clinical trial of its FAP-Exd (AVA6103) program in Q1 2026.
Christina Coughlin, CEO of Avacta commented,
"Our analysis demonstrates three potential advantages of our proprietary pre|CISION delivery mechanism when compared to the marketed ADC, Enhertu®: more rapid drug penetration into the tumor, a one log higher absolute maximum drug concentration in the tumor and the Tumor Selectivity Index (a critical safety and effectiveness measure) being nearly three-fold higher.
"This data analysis supports our belief that our pre|CISION payload delivery mechanism has many key advantages over the ADC mechanism, currently one of the most successful drug classes in oncology.
"This innovative use of AI to recreate a synthetic comparator arm also demonstrated the creativity and expertise of our team. This synthetic comparator allows a direct comparison of the FAP-Exd data with the data published by the Enhertu® team, rather than repeating their experiments in-house.
"We believe the observations in this dataset have significantly increased the probability of success with FAP-Exd, given both the ability of FAP-Exd to deliver more payload selectively to the tumor in the preclinical setting and success of Enhertu® in the clinic. We look forward to the start of the clinical trial."
The analysis uses a synthetic comparator arm that was generated using AI to recreate a published AstraZeneca data set1 and compare to experimental data generated with FAP-Exd (AVA6103) in a similar experimental design using a FAP-high animal model with two drugs using similar payloads (exatecan and deruxtecan).
The analysis demonstrates three key pharmacokinetic (PK) advantages in the kinetics of the release of payload, specifically:
- AVA6103 results in more rapid drug penetration into the tumor, with the maximal concentration (Cmax) in tumor tissue occurring within minutes of dosing compared with T-Dxd maximum concentration observed at 24 hours;
- The observed absolute maximum concentration (Cmax) observed with FAP-Exd in the tumor was more than a log higher than the Cmax observed with T-Dxd; and
- The Tumor Selectivity Index (TSI, ratio of the area under the curve (AUC) observed over 14 days in the tumor v. plasma) was nearly three-fold higher with pre|CISION® delivery (FAP-Exd) versus ADC delivery (T-Dxd).
Avacta's scientists have also described two key impacts of these PK differences in animal efficacy models, including (1) higher activity of FAP-Exd in tumor models having the lowest observed expression of FAP compared with variable activity of T-Dxd at low expression levels of HER2 and (2) deep, durable responses that are observed to persist for many weeks after the 3 dose regimen with FAP-Exd.
Avacta scientists plan to present these data at an upcoming scientific congress and submit to a peer-reviewed journal in the near future.
Enhertu is a registered trademark of AstraZeneca and Daiichi Sankyo.
1Vasalou C, et al. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. CPT Pharmacometrics Syst Pharmacol. 2024 (6):994-1005. doi: 10.1002/psp4.13133 (AZ nonclinical data)
For further information from Avacta, please contact:
| Avacta Group plc Christina Coughlin, Chief Executive Officer | https://avacta.com/ via Cohesion Bureau |
| Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance | www.strandhanson.co.uk |
| Zeus (Broker) James Hornigold / George Duxberry / Dominic King | www.zeuscapital.co.uk |
| Cohesion Bureau (Communications) Richard Jarvis / Chris Maggos | avacta@cohesionbureau.com |
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.
Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
FAQ**
How does Avacta Group Plc AVCTF plan to leverage the new experimental data demonstrating the advantages of FAP-Exd over Enhertu® in their upcoming Phase 1 clinical trial expected to start in Q1 2026?
What specific strategies will Avacta Group Plc AVCTF employ to maximize investor confidence in light of the favorable results comparing their pre|CISION platform with the established ADC model?
Can Avacta Group Plc AVCTF share insights on the anticipated regulatory pathway and timeline for FAP-Exd following the upcoming Phase 1 trial initiation in Q1 2026?
How does Avacta Group Plc AVCTF plan to present the published data from their analysis at scientific congresses and peer-reviewed journals to further validate their pre|CISION platform's efficacy?
**MWN-AI FAQ is based on asking OpenAI questions about Avacta Group Plc (OTC: AVCTF).
NASDAQ: AVCTF
AVCTF Trading
0.0% G/L:
$0.9794 Last:
100 Volume:
$0.9794 Open:
